← Back to Screener
Xtant Medical Holdings, Inc. (XTNT)
Price$0.48
Favorite Metrics
Price vs S&P 500 (26W)-30.14%
Price vs S&P 500 (4W)-19.62%
Market Capitalization$69.67M
P/E Ratio (Annual)14.01x
All Metrics
P/CF (Annual)5.55x
Book Value / Share (Quarterly)$0.36
P/TBV (Annual)2.17x
Revenue Growth (3Y)32.20%
Cash Flow / Share (Quarterly)$0.07
Price vs S&P 500 (YTD)-38.87%
Gross Margin (TTM)62.92%
Net Profit Margin (TTM)3.71%
EPS (TTM)$0.03
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$0.03
Revenue Growth (5Y)20.22%
EPS (Annual)$0.03
ROI (Annual)6.51%
Gross Margin (Annual)62.92%
Net Profit Margin (5Y Avg)-6.60%
Cash / Share (Quarterly)$0.12
P/E Basic Excl Extra (TTM)14.01x
Revenue Growth QoQ (YoY)2.68%
P/E Normalized (Annual)14.01x
ROA (Last FY)5.28%
Revenue Growth TTM (YoY)14.21%
EBITD / Share (TTM)$0.11
ROE (5Y Avg)-13.55%
Operating Margin (TTM)7.89%
Cash Flow / Share (Annual)$0.07
P/B Ratio1.37x
P/B Ratio (Quarterly)2.15x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)0.58x
Net Interest Coverage (TTM)2.92x
ROA (TTM)4.98%
EV / EBITDA (TTM)4.92x
EPS Incl Extra (Annual)$0.03
Current Ratio (Annual)2.65x
Quick Ratio (Quarterly)1.55x
3-Month Avg Trading Volume0.18M
52-Week Price Return25.00%
EV / Free Cash Flow (Annual)7.68x
P/E Incl Extra (TTM)14.01x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.36
P/S Ratio (Annual)0.52x
Asset Turnover (Annual)1.42x
52-Week High$0.95
Operating Margin (5Y Avg)-3.87%
EPS Excl Extra (Annual)$0.03
CapEx CAGR (5Y)9.04%
Tangible BV CAGR (5Y)29.22%
26-Week Price Return-26.16%
Quick Ratio (Annual)1.55x
13-Week Price Return-29.03%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)2.65x
Enterprise Value$78.047
Revenue / Share Growth (5Y)-13.76%
Asset Turnover (TTM)1.34x
Book Value / Share Growth (5Y)14.22%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.44x
Pretax Margin (Annual)5.23%
Cash / Share (Annual)$0.12
3-Month Return Std Dev49.61%
Gross Margin (5Y Avg)59.21%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)64.22%
EBITDA Interim CAGR (5Y)45.07%
ROE (Last FY)9.76%
Net Interest Coverage (Annual)2.92x
EPS Basic Excl Extra (Annual)$0.03
P/FCF (TTM)6.85x
Receivables Turnover (TTM)6.96x
EV / Free Cash Flow (TTM)7.68x
Total Debt / Equity (Quarterly)0.50x
EPS Incl Extra (TTM)$0.03
Receivables Turnover (Annual)6.96x
ROI (TTM)6.30%
P/S Ratio (TTM)0.52x
Pretax Margin (5Y Avg)-6.61%
Revenue / Share (Annual)$0.89
Tangible BV / Share (Annual)$0.36
Forward P/E45.04x
Price vs S&P 500 (52W)-4.83%
P/E Ratio (TTM)14.01x
Year-to-Date Return-36.22%
5-Day Price Return5.31%
EPS Normalized (Annual)$0.03
ROA (5Y Avg)-6.90%
Net Profit Margin (Annual)3.71%
Month-to-Date Return-10.39%
Cash Flow / Share (TTM)$0.05
EBITD / Share (Annual)$0.11
Operating Margin (Annual)7.89%
LT Debt / Equity (Annual)0.22x
P/CF (TTM)5.55x
ROI (5Y Avg)-8.27%
P/E Excl Extra (TTM)14.01x
LT Debt / Equity (Quarterly)0.22x
EPS Basic Excl Extra (TTM)$0.03
P/TBV (Quarterly)2.17x
P/B Ratio (Annual)2.15x
Inventory Turnover (TTM)1.44x
Pretax Margin (TTM)5.23%
Book Value / Share (Annual)$0.36
Price vs S&P 500 (13W)-29.72%
Beta-0.17x
P/FCF (Annual)6.85x
Revenue / Share (TTM)$0.89
ROE (TTM)10.27%
52-Week Low$0.39
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
XTNTXtant Medical Holdings, Inc. | 0.52x | 20.22% | 62.92% | 7.89% | $0.48 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Xtant Medical Holdings develops and commercializes orthobiologics and spinal implant systems for complex spinal fusion, deformity, and degenerative procedures. Its product portfolio includes OsteoSponge, OsteoSelect Plus, OsteoWrap, and 3Demin allografts, sold to orthopedic spine surgeons and neurosurgeons. The company generates the majority of its revenue from the U.S. market.